Slingshot members are tracking this event:
Agios' (AGIO) Phase 1 TIBSOVO (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML) Translational Data Released
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
Slingshot Insights Explained
Dec 09, 2019
Don’t see a project related to the catalyst you care about?
Related Keywords Idh1 Mutation, Acute Myeloid Leukemia, Tibsovo, Ivosidenib